International Aids Vaccine Initiative

About International Aids Vaccine Initiative

International Aids Vaccine Initiative Inc. centers its grantmaking on turning scientific discoveries into affordable, globally accessible public health solutions. Its recent awards show a strong emphasis on research and development, with repeated support for institutions working on HIV vaccines, HIV antibodies and broadly neutralizing antibodies, tuberculosis vaccines, and emerging infectious diseases. The largest recent grants in the dataset went to The Scripps Research Institute - Osp in La Jolla, California, and to Texas Biomedical Research Institute in San Antonio, Texas, reflecting a portfolio built around laboratory and translational work rather than broad program support. The foundation’s funding also reaches clinical development and implementation research. Boston University appears multiple times among recipients, while Seattle Children’s Hospital, Emory University, and the University of Texas Medical Branch Galveston are also recurring recipients. Active grant programs in the record include requests tied to clinical-lot manufacturing for HIV vaccine immunogens, a clinical trial management system, a research literacy mobile application, and a market assessment for HIV bnAbs. Together, these patterns point to a funder investing in the technical steps that move vaccine and antibody research toward use.

What International Aids Vaccine Initiative Funds

HIV vaccines are a central theme. In 2025, International Aids Vaccine Initiative Inc. gave $2,739,912 to The Scripps Research Institute - Osp in La Jolla for research and development, and in 2024 it gave $3,088,050 to the same recipient for the same purpose. The foundation also supports HIV antibody work: in 2025 it awarded $1,375,993 to Fhi Clinical Inc in Durham for research and development, alongside an active RFP for a market assessment for HIV bnAbs for prevention and treatment. Its portfolio extends to other biomedical areas as well. Texas Biomedical Research Institute received $2,385,977 in 2023 and $1,667,115 in 2024 for research and development, and the University of Texas Medical Branch Galveston received $1,556,250 in 2023. The foundation also funds global access and research-support tools, including a research literacy mobile application solicitation and a clinical trial management system RFP.

How International Aids Vaccine Initiative Gives